Investors looking for a post-election idea may want to consider the ETF highlighted in today’s article, which tracks an index “comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration (FDA) clinical trials.” For more on this ETF and why election-year market history is on its side, CLICK HERE.